Molecular driver alterations and their clinical relevance in cancer of unknown primary site. - Wikidata - awgldk - TriplyDB

Molecular driver alterations and their clinical relevance in cancer of unknown primary site.

Molecular driver alterations and their clinical relevance in cancer of unknown primary site.

http://www.wikidata.org/entity/Q37536877

about

Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: A case report.

P2860

Q38697494-0990B498-5E9C-4A73-B605-2086B3050487 Q50003117-A045CF7E-5D83-4789-A6AF-17E52DE2CB37

P2860

Molecular driver alterations and their clinical relevance in cancer of unknown primary site.

http://www.wikidata.org/entity/Q37536877

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Molecular driver alterations a ...... ancer of unknown primary site.

@en

Molecular driver alterations a ...... ancer of unknown primary site.

@nl

type

label

Molecular driver alterations a ...... ancer of unknown primary site.

@en

Molecular driver alterations a ...... ancer of unknown primary site.

@nl

prefLabel

Molecular driver alterations a ...... ancer of unknown primary site.

@en

Molecular driver alterations a ...... ancer of unknown primary site.

@nl

P1433

Q37536877-AAD8B5FE-B207-4D32-B646-0B2E39FF1B08

P1476

Q37536877-8EDE8F56-508C-4180-B2B0-68BF2215C6C2

P2093

Q37536877-1E4FC618-9564-4AD2-92B0-6D44F4DF2B76

Q37536877-3A58C236-BFBE-43CF-A0A0-B0D6CC7A6022

Q37536877-58592869-7F3E-4FAF-A1E3-883CA59CEA75

Q37536877-5F691F74-921A-478F-BAF6-61252DF84CF0

Q37536877-6739AED9-C37C-4FCD-8B73-8E9F3E6A19EE

Q37536877-79FE6C2A-45AE-4BCF-A2F5-DD474A7350A3

Q37536877-7DF8B411-5CCA-4BAA-98FC-D98CE7C2980F

Q37536877-A65B89E9-EBD8-4878-A95E-B8CA23F9629F

Q37536877-D9E0D5BE-BE52-4918-86D0-F8CD5B9F054C

P2860

Q37536877-063B7DC4-57BF-4294-A22B-33F9FBA1E30E

Q37536877-105760C4-C846-4740-BE68-3EE68B5683C1

Q37536877-157F9427-6F0F-46E6-9DCB-999AC97E6612

Q37536877-19B58FEA-20ED-4CAA-B19D-EFE8BD7707AD

Q37536877-21E1A769-6D7B-4A67-95B3-19F967D5DEE8

Q37536877-2CE46938-6791-44E5-9D9B-BAFAA73D4D40

Q37536877-35BFB9E6-E73B-4C36-A6DE-B0C88A3F1605

Q37536877-39FADA2C-63D2-4CBF-8125-6112F7B1DB2A

Q37536877-3D5C1108-3469-47EC-86A4-EE63623DD9F7

Q37536877-3D6FA8D2-FD85-4FBD-BB12-5BECD9EDA344

P304

Q37536877-C7D5C5CF-3A43-4E29-B5DE-4B53081B0FDC

P31

Q37536877-A251D860-A71C-42FC-892C-FDDE66D26AF4

P356

Q37536877-29A0CCAB-1177-489C-89E4-E7BA742F7222

P407

Q37536877-7D98C9E3-E712-405D-BF1E-F6CD192B9EB5

P433

Q37536877-8A176BA0-6087-4C2A-A0E2-7AB9ECE98F5C

P478

Q37536877-A3488714-321E-4890-8AE5-C22DCDF8B4C2

P50

Q37536877-32AE7BB9-EAD1-47DA-8E43-C14378C71892

Q37536877-8CADDF0D-4000-4EFA-98D9-FFCF5D93CC12

P577

Q37536877-A1698DB9-E37E-4C54-BC01-C55BF5ADB212

P698

Q37536877-45BF1E54-5ADA-4927-9A6B-414DE04F3AED

P932

Q37536877-C8429E7E-22C2-4431-AEC7-9778118AF58A

P356

ONCOTARGET.10035

P1433

P1476

Molecular driver alterations a ...... ancer of unknown primary site.

@en

P2093

Albrecht Stenzinger

http://www.w3.org/2001/XMLSchema#string

Alwin Krämer

http://www.w3.org/2001/XMLSchema#string

Gunnar Folprecht

http://www.w3.org/2001/XMLSchema#string

Harald Löffler

http://www.w3.org/2001/XMLSchema#string

Mark Kriegsmann

http://www.w3.org/2001/XMLSchema#string

Nicole Pfarr

http://www.w3.org/2001/XMLSchema#string

Philipp Lohneis

http://www.w3.org/2001/XMLSchema#string

Thomas Hielscher

http://www.w3.org/2001/XMLSchema#string

Volker Endris

http://www.w3.org/2001/XMLSchema#string

P2860

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

TP53 mutation and survival in chronic lymphocytic leukemia.

Acute Myeloid Leukemia

The Path to Personalized Medicine

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

EGFR antagonists in cancer treatment

Patients with cancer of unknown primary: a retrospective analysis of 223 patients with adenocarcinoma or undifferentiated carcinoma

Assessing TP53 status in human tumours to evaluate clinical outcome.

P304

44322-44329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.10035

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27322425

http://www.w3.org/2001/XMLSchema#string

P932

5190099

http://www.w3.org/2001/XMLSchema#string